Ovarian Cancer
📧 Sign up to get email alerts when something new happens for Ovarian Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-01-05Clinical Trial Update: GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer [Phase 1, Phase 2]
Clinical trial update for GL-ONC1 oncolytic immunotherapy in recurrent or refractory ovarian cancer (Phase 1/Phase 2) completed.
-
CLINICAL_TRIALS trial_result · 2023-01-03Clinical Trial Update: Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy [Phase 2]
Phase 2 trial evaluating pamiparib with tamoxifen for epithelial ovarian cancer patients with biochemical recurrence during first-line PARP …
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse [Phase 3]
Phase 3 trial of farletuzumab with carboplatin and taxane in platinum-sensitive ovarian cancer at first relapse was terminated; results post…
-
CLINICAL_TRIALS trial_result · 2022-12-30Clinical Trial Update: Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer [Phase 2]
Phase 2 trial update on neoadjuvant chemotherapy for epithelial ovarian cancer with related fallopian tube and peritoneal carcinomas; curren…
-
CLINICAL_TRIALS trial_result · 2022-12-23Clinical Trial Update: Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer [Phase 2]
This Phase 2 trial evaluated the activity of combining nivolumab and ipilimumab in patients with recurrent or persistent clear cell ovarian …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-12-22Clinical Trial Update: A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies [Phase 1, Phase 2]
Phase 1/2 trial evaluating ONCOS-102 in combination with durvalumab in advanced peritoneal malignancies (colorectal, ovarian, and appendicea…
-
FDA approval · 2022-12-16FDA Approved: CYTALUX — Supplemental Application (On Target Laboratories, Inc.)
FDA approved a supplemental application for CYTALUX (pafolacianine injection) by On Target Laboratories, expanding the product's labeling. T…
-
CLINICAL_TRIALS trial_result · 2022-12-15Clinical Trial Update: Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer [Phase 2]
Phase 2 trial comparing Folate Receptor Alpha Peptide Vaccine with GM-CSF versus GM-CSF alone in platinum-sensitive ovarian cancer was termi…
-
CLINICAL_TRIALS trial_result · 2022-12-07Clinical Trial Update: A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating Yangzhengxiaoji Capsule added to niraparib maintenance therapy to improve nausea in ovarian cancer.
-
CLINICAL_TRIALS trial_result · 2022-10-28Clinical Trial Update: Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer [Phase 2]
A Phase 2 clinical trial update evaluating Fluzopari in combination with Apatinib for neoadjuvant treatment of unresectable ovarian cancer. …
-
CLINICAL_TRIALS trial_result · 2022-10-25Clinical Trial Update: Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [Phase 2]
Phase 2 clinical trial evaluating gemcitabine hydrochloride alone or in combination with M6620 for recurrent ovarian, fallopian tube, or pri…
-
FDA approval · 2022-10-20FDA Approved: PACLITAXEL — Original Application (BluePoint Laboratories)
FDA approves paclitaxel as a generic product under an original application from BluePoint Laboratories.
-
CLINICAL_TRIALS trial_result · 2022-10-05Clinical Trial Update: Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation [Phase 2]
Phase 2 trial evaluating the combination of olaparib, durvalumab, and tremelimumab in patients with BRCA1/BRCA2-mutated recurrent or refract…
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients [Phase 3]
Phase 3 clinical trial evaluating maintenance olaparib with cediranib vs olaparib alone in ovarian cancer; status not specified.
-
CLINICAL_TRIALS trial_result · 2022-09-27Clinical Trial Update: Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab [NA]
Clinical trial assessing perfusion CT to predict outcomes in ovarian, fallopian tube, or peritoneal cancer treated with bevacizumab; the stu…
-
CLINICAL_TRIALS trial_result · 2022-09-26Clinical Trial Update: Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy [Phase 4]
Phase 4 trial assessing aspirin for prevention of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy has c…
-
CLINICAL_TRIALS trial_result · 2022-09-23Clinical Trial Update: Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma [Phase 2]
Phase 2 clinical trial update evaluating olaparib after response to trabectedin-pegylated liposomal doxorubicin in recurrent ovarian carcino…
-
CLINICAL_TRIALS trial_result · 2022-09-21Clinical Trial Update: Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer [Phase 2]
Phase 2 trial evaluating a vaccine therapy with paclitaxel and carboplatin in patients undergoing surgery for advanced ovarian cancer, prima…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer [Phase 2]
Phase II single-arm pilot study of the Chk1/2 inhibitor LY2606368 in BRCA1/2 mutation-associated breast or ovarian cancer, triple negative b…
-
CLINICAL_TRIALS trial_result · 2022-09-10Clinical Trial Update: Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy [Phase 2]
Phase 2 trial evaluating regorafenib in metastatic solid tumors that progressed after standard therapy has completed, with multiple indicate…
-
CLINICAL_TRIALS trial_result · 2022-09-01Clinical Trial Update: Effect of Hemp-CBD on Patients With CIPN [Phase 2]
Phase 2 clinical trial investigating the effect of hemp-derived CBD on chemotherapy-induced peripheral neuropathy.
-
CLINICAL_TRIALS trial_result · 2022-08-30Clinical Trial Update: Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer [Phase 1, Phase 2]
Phase 1/2 trial comparing niraparib alone to niraparib with bevacizumab in platinum-sensitive epithelial ovarian cancer; study completed.
-
CLINICAL_TRIALS trial_result · 2022-08-29Clinical Trial Update: A Study of Niraparib in Patients With Relapsed Ovarian Cancer [Phase 2]
Phase 2 trial evaluating niraparib in relapsed ovarian cancer has completed.
-
CLINICAL_TRIALS trial_result · 2022-08-29Clinical Trial Update: A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation [Phase 2]
Phase 2 trial of BBI503 in asymptomatic recurrent ovarian cancer with CA-125 elevation was terminated; results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-08-15Clinical Trial Update: A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer [Phase 3]
A Phase 3 clinical trial update for navicixizumab in platinum-resistant ovarian cancer is underway, with status currently unknown.